This chapter is related to Section U2(i) and U2(v) from the 2017 CICM Primary Syllabus, which expects the exam candidate to "understand the pharmacology of glucocorticoids" and "understand the pharmacology of mineralocorticoids". After some agonising self-examination, the author concluded that it would serve the readers' psychological safety better to have this section separate from the rest, instead of grafting the entire corticosteroid pharmacology summary together into one 10,000-word abomination. Whereas the chapters on adrenal physiology deal with the physiological regulatory effects of endogenous cortisol and aldosterone, the following summary pertains to the effects of potent exogenous corticosteroid drugs, which are treated as a completely separate topic mainly because that is how it tends to appear in exams. Having said this, the CICM exam is notably without any questions on steroid side effects, which means most readers can safely stop reading at the end of this little grey box:
Rapid non-genomic effects (minutes)
- Reduction of bronchial blood flow and oedema
- Haemodynamic effects: enhanced vasoconstriction and contractility
- Increased sensitivity to catecholamines
- Decreased activity of ATP-sensitive potassium channels
- Decreased induction of nitric oxide synthase
- Increased skeletal muscle power and endurance
Genomic effects (hours)
- Immunosuppressant effects:
- Increased release of neutrphils from bone marrow, but decreased neutrophil migration, phagocytosis and degranulation (all this manifests as a peripheral leukocytosis)
- Suppression of inflammatory mediator release from granulocytes and lymphocytes
- Reduction of airway oedema
- Cardiovascular effects: enhanced vasoconstriction and contractility
- Decreased myocardial sensitivity to endotoxin
- Decreased transcription and expression of nitric oxide synthase
- Neuropsychiatric effects (euphoria, mania, insomnia, psychosis)
- Metabolic effects:
- Hyperglycaemia due to decreased peripheral insulin sensitivity and the increased gluconeogenesis in the liver
- Skeletal muscle catabolism and redistribution of amino acids to the liver to act as metabolic substrate
- Peripheral lipolysis and liberation of free fatty acids
- Mineralocorticoid-related fluid and electrolyte effects:
- Hypernaremia, hypokalemia, water retention
- Adrenal suppression (with long courses > 2 weeks, multiple daily doses, long-acting steroids such as dexamethasone)
Delayed consequences of genomic effects (days, weeks)
- Acute steroid myopathy and skeletal muscle protein loss (eg. in critical illness)
- Immunosuppressant effects:
- Dendritic cell apoptosis, immune anergy
- Decreased B and T lymphocyte numbers and function
- Decreased immunoglobulin synthesis
- Impaired wound healing (decreased wound tensile strength by ~ 30%)
- Increased risk of anastomotic breakdown and peptic/gastric ulceration
Gradual remodelling (months)
- Antiproliferative airway smooth muscle effects
- Fatty tissue redistribution (buffalo hump, moon facies, etc)
- Avascular bone necrosis (mainly heads of femur)
- Chronic steroid myopathy
- Increased risk of opportunistic infections (Aspergillus, Pneumocystis, Strongyloides)
- Psychological dependence
Links with specific articles are offered below under the relevant headings, which is the authors' cowardly method of outsourcing all the responsibility for explaining the detailed pathophysiological mechanisms to scientists and clinicians who actually understand them. The effects are obviously many, and it seems like each of them has had a group of dedicated investigators, which is something we can benefit from. The harried CICM trainee will of course have no time for any of that, and they can be referred to a single free article such as Fardet et al (2007) which covers all the adverse effects of steroids under a single structure. It is also only about twelve pages, making it manageable.
It would have probably been criminal to leave this at the bottom of this chapter, as it is clearly the main reason people tend to use corticosteroids, and so it should occupy a position of prominence. And there is probably no better way to enhance that prominence than by namedropping a prominent author. Hence, it is probably worth mentioning with feigned nonchalance that the structure and content of the material below was mainly informed by an excellent article about this topic by none other than Anthony S. Fauci, written in 1978, many years before his war against the Sith. Obviously a few things have happened in the last fifty years, and more recent papers such as Baschant & Tuckermann (2010) are also available to shed light on this matter, but it never hurts to reference the classics, especially considering that the scientific progress into steroid immunology over those decades has mainly involved nightmarish contortions of molecular biology which the CICM exam candidate is not expected to remember anyway. The basic observations about how steroids affect the immune system have remained substantially the same since 1978.
Anyway, you could probably split the immune effects of corticosteroids into two broad groups, one of which is the effects on the innate immunity (which could be described as their "anti-inflammatory" activity) and the effects on specific immunity which relate more to lymphocyte function.
What the hell does this mean, exactly:
After the shouting and blame-pointing is finished when a patient is emergently reintubated for post-extubation stridor, junior ICU doctors are often asked to prescribe some corticosteroids (usually dexamethasone) to reduce the vocal cord oedema and promote a more successful extubation attempt on the following day. The use of corticosteroids to reduce airway oedema is actually a very old-school approach that appears to have existed for many decades, and it has come to the ICU mainly from otolaryngology practice, where it was used for basically any nonspecific vaguely inflammatory swelling. Hawkins et al (1983) describe brutal ancient steroid rituals going back to the 1960s, for example for the management of epiglottitis and laryngotracheobronchitis, but also less clearly inflammatory processes like vocal cord trauma. This appears to be some sort of subacute effect, in the sense that most authorities would recommend waiting for at least 24 hours before trying something new with the swollen airway. This is on the basis of the observation that studies giving steroids 30-60 minutes prior to a planned extubation all failed to demonstrate any reduction in the incidence of stridor, whereas those that started steroids 12-24 hours earlier were almost uniformly successful.
Putting aside their obvious immunomodulatory effects on the functions of mast cells and IgE-mediated hypersensitivity, steroids also seem to have direct effects on bronchial smooth muscle reactivity. Hirst & Lee (1998) outlined a lot of the proposed mechanisms, which range from direct effects on contractile intracellular proteins, effects on the availability of intracellular calcium, the effect of uncoupling smooth muscle vasoconstrictor receptors (such as histamine) and potentiation of relaxation by the increase of Na+/K+ ATPase activity and catecholamine sensitivity. It appears these effects are observed over the timeframe of hours, which suggests that this is a genomic effect, dependent on protein transcription. Long-term use tends to take over the processes of smooth muscle cell proliferation, which is where steroids help prevent the unhelpful chronic hyperproliferative response that makes chronic airflow limitation irreversible.
Additionally, steroids reduce the blood flow to the bronchial mucosa, decreasing the hyperaemia of inflammation and infection. Various experiments have demonstrated that this is some kind of rapid, non-genomic effect, mediated probably by membrane-bound glucocorticoid receptors. The effect of inhaled fluticasone, for example, was very acute for Kumar et al (2000), with the nadir of mucosal blood flow reached around 30 minutes after the dose.
An ancient paper by Weil (1962) is still the best description (if not explanation) of what happens to haemodynamics and cardiovascular performance in response to systemic steroid therapy. Broadly, the intensivist would describe these as "everything better", whereas a cardiologist would describe them as "everything worse". Clinically, steroids produce:μ
A lot of the haemodynamic effects are owed to the increased sensitivity of various key components of the cardiovascular system to catecholamines. In the presence of steroids, noradrenaline works harder. Ullian (1999) outlines the experiments which have confirmed and defined this effect, and Boyer et al (2006) explain some of the cellular mechanisms (not that they are particularly well-understood). The bottom line is that vessel and cardiovascular reactivity to catecholamines is increased within minutes to hours, by some sort of non-genomic mechanism. In case you are interested, this effect seems to dissipate after about 36 hours following the cessation of steroids, according to some early human experiments by Kurland & Freedberg (1951).
Additionally, vessel tone seems to improve by some other non-catecholamine-related mechanism. Nobody seems to know the exact way this happens, but some tantalising information has come from experiments by d'Emmanuele di Villa Bianca et al (2006), who tested the effects of dexamethasone on vascular reactivity. From these, it appears that the steroid had immediately antagonised the action of ATP-sensitive potassium channels (normally responsible for regional blood flow autoregulation in arterioles). This means that steroids might be acting basically as anti-hydralazine, exerting something of a direct vasopressor (or at least counter-dilator) effect.
Furthermore corticosteroids seem to defend the circulatory system from a lot of the nastiness of systemic inflammatory responses. Of particular interest is their effect on suppressing the endotoxin-mediated induction of nitric oxide synthase (within about an hour), and their cardioprotective effects which defend the myocardial cells against the depressant effects of endotoxin. Multiple different mechanisms have been identified which seem to be responsible for these effects, and they are listed in the chapter on the use of steroids in septic shock, because that is where these effects are most important. The reader who is interested in a more professional take on this topic is redirected to some excellent corticosteroid propaganda by Djillale Annane (2011).
Lastly, it appears that mega-dose steroid pulses have other, poorly characterised and unexplained effects on the cardiovascular system. When Jain et al (2005) subjected thirty pemphigoid patients to pulse therapy, they observed all sorts of abnormalities, such as sinus bradycardias and an increase in the number of arrhythmias and ventricular ectopics. No explanation for this was offered, other than a series of theoretical notes on potential cellular mechanisms.
A veteran intensivist formerly in the authors' orbit had at one stage narrated to him an account of how he, following an injection of betamethasone into an aching shoulder, spent the whole night working feverishly on a solution to the political turmoil in the Middle East. In short, steroids can make a raving loon of any formerly normal person, given enough time and a high enough dose. Ciriaco et al (2013) probably offers the best review of these central nervous system effects. To try to explain these has eluded the best of thinkers, which means the rest of us will have to satisfy ourselves with merely listing them:
Good feels and abundant energy are not the uniform effect: some people actually report a worsening of their depression, or a decreased ability to regulate their mood. In case you are wondering what sort of steroid dose is needed to drive somebody insane, the answer is probably "a large dose"; a large retrospective audit from the 1970s found that the patients who received less than 40mg/day of prednisolone were highly unlikely to develop worsening features of psychosis (less than 1.3% of them did), whereas with doses in excess of 80mg about 18% of the patients became psychotic. This is clearly some sort of genomic effect, as it is not something seen abruptly - in most cases it takes about five days of treatment with normal doses, or about 24 hours with pulses.
Though we might commonly associate steroids with proximal myopathy, it might seem logical that, when you're having a "stress response", some increased muscle strength and endurance would be a desirable effect from your stress hormones. This, reader, is exactly what happens from small and transient steroid courses- to the point where professional athletes can use these drugs to gain a competitive edge. As an example, when Casuso et al (2013) gave a mere 2mg of daily dexamethasone to a group of random males for five days, they found that with even this trivial dose they were able to perform a repetitive leg extensor exercise for 29% longer than without it.
However, as everyone knows, this is a transient effect. Over time corticosteroids gradually produce myopathy, mainly as the result of their effects on protein metabolism and muscle RNA synthesis. Gupta & Gupta (2013) have probably the fastest most readable article on this subject, where the interested reader can turn for a little more detail; but without going in too deep, the mechanism involves the simultaneous depression of protein synthesis and the activation of structural protein catabolism, with the ubiquitin-proteasome and lysosome systems actively involved in degrading myofibrils. The result is muscle atrophy, which is something only seen over the course of months for patients in the community (presumably because they continue to use their muscles), or over the course of days and weeks for ICU patients, because they are immobile and critically ill. That sort of "acute" steroid myopathy is the one that is probably of the greatest interest to the intensivist. It probably has a slightly different underlying mechanism, as it progresses very rapidly (Haran et al report a time course of only three days for some patients), with some authors suggesting that this form is mainly non-genomic.
Virtually all corticosteroids (other than dexamethasone and betamethasone) have some sort of mineralocorticoid effect, which manifests itself as a trend to increase the total body sodium and decrease the total body potassium by the activity of the aldosterone-regulated ENaC channel in the distal nephron. Detailed discussions of renal handling of sodium and potassium are available elsewhere, and here it will suffice to note that this effect will be most pronounced when the normal water retention which is expected from these effects is somehow countered, like for example with the use of diuretics or with GI losses. The consequence is the concentration of sodium in the extracellular fluid, leading to an increase in the strong ion difference and therefore metabolic alkalosis.
So that's an undesirable excess of mineralocorticoid effect, generally seen with hydrocortisone and prednisolone more than with the other drugs. Dexamethasone and methylprednisolone tend not to have as much mineralocorticoid effect (dexamethasone in fact has none), which is one of the reasons that these drugs are preferred as the agents of choice for big steroid doses. However, over time, the use of these "pure" glucocorticoid agents can result in an undesirable deficit of mineralocorticoid activity. The main reason for this is the suppression of ACTH release. ACTH is suppressed by anything with a glucocorticoid effect, which means that in the sustained presence of something like dexamethasone or methylprednisolone ACTH secretion will decrease. This means aldosterone secretion will also decrease, as ACTH is an important aldosterone secretagogue. At the same time the "pure" glucocorticoid agent has no mineralocorticoid effect of its own. The result of this looks a little bit like primary hypoaldosteronism, or the consequences of spironolactone therapy: hyponatremia hyperkalemia and a normal anion gap acidosis typically ensue. For this reason, the reader will probably be unable to recall ever seeing any patients on long-term oral dexamethasone; it is usually converted to an equivalent dose of prednisolone for chronic maintenance therapy, mainly for these sorts of reasons.
Following from the above, it is worth mentioning the effect of corticosteroids on the hypothalamic-adrenal-pituitary axis that regulates the normal secretion of cortisol. One is reminded that this set of regulatory organs only has one sensor available to detect steroid concentrations, and this is the easily fooled glucocorticoid receptor. All steroids with a glucocorticoid effect are therefore likely to confuse the hypothalamus and pituitary. However, not all steroid courses will have the same effect. There are notable differences in the degree and duration of adrenal suppression, which depend on several factors, listed in detail by Helfer & Rose (1989):
Helfer & Rose (1989) suggest that about 2-3 weeks of moderate-intensity steroid therapy should still allow an abrupt cessation of the steroid, without the fear of adrenal suppression. However, that person may still have sub-normal adrenal function (just not low enough to be significant for their daily function). They will still attend their day job, but any exposure to physiological stress (eg. surgery) may expose a hidden adrenal insufficiency.
They don't call them glucocorticoids for nothing. If you considered yourself to be an open-minded glucose-tolerant person before, steroids will change that very quickly. If you had diabetes and considered it to be under good control, you can say goodbye to that as well. This effect seems to be dose-dependent, and has several mechanisms:
The net effect is hyperglycaemia. According to Poetker & Reh (2010) and Radhakutty & Kurt (2018), the peak changes are seen within 8-12 hours of starting therapy, i.e. roughly at the same time that you should be seeing other genomic effects (such as the peak antiinflammatory activity).
The purpose of this, from a "why would the body do that" point of view, remains somewhat obscure. It appears that cortisol, like growth hormone and glucagon, are counterregulatory signals designed to balance the effects of insulin, which means that the hyperglycaemia we see with exogenous steroids is probably just an exaggeration of that effect, and not a part of a normal stress response. You can clearly see what would happen without these regulatory effects in the hypoglycaemia which presents along with Addison disease, where there is no cortisol to oppose the influence of insulin. Andrews & Walker (1999) offer a more rigorous breakdown, in case that is what is required, but the CICM First Part exam candidate is reminded that we are very far from core syllabuses knowledge here, and this is unlikely to ever appear in any of the papers or vivas.
The acute administration of corticosteroids results in an increase in the lipolysis taking place in adipose tissue. The intracellular molecular mechanisms of this are likely to be of little interest to the pragmatic intensivist, as there are no practical means of manipulating them, nor is there any reason to do so. Those who would like to know more are motioned towards Xu et al (2009), where the details are discussed. From the point of view of the ICU patient, this looks like an increase in the release of free fatty acids, and it contributes to the fatty liver disease which is often seen with corticosteroid therapy.
At the same time, with chronic use, the user sees a redistribution of fat around the body, with a net increase in adipose tissue (some of which can be attributed to the increased appetite), but increased more in some places than in others. Clinically, this gives rise to the central obesity, typical "moon facies" and "buffalo hump" (dorsocervical fat pad) seen with chronic steroid use or Cushing's disease. This is obviously not something you would see over the period of a short ICU stay: it typically takes a long time to develop this sort of appearance, and the dose required is usually substantial. For example, rat studies by Rebuffe-Scrive et al (1992) suggest that, though some mesenteric fat deposition does occur with chronic stress, the native adrenal glands probably do not produce enough cortisol to push fat around on an industrial scale, i.e. exogenous corticosteroids are required. Poetker & Reh dig out some studies suggesting that modest doses (10-30mg of prednisolone) for modest periods (3 months) have a modest chance (15%) of producing this complication.
Corticosteroids reduce the rate of protein synthesis in skeletal muscle, and in fact favour protein catabolism and the generation of glucose from amino acids liberated by this process. Without going into the thick forest of molecular biology presented by Magomedova & Cummins (2015) it is possibly better to just summarise that steroids cause muscle cells to preferentially degrade functional myofibrillar components (eg. myosin heavy chain) and various essential-sounding regulatory proteins, with the ultimate outcome being atrophy and myopathy.
At the same time, the effects of glucocorticoids on the myocardium are completely the opposite: Ren et al (2012) found that they tend to increase the synthesis of bulky contractile proteins, and produce cardiac myocyte hypertrophy. Even more weirdly, this is not a mineralocorticoid effect, i.e. aldosterone definitely does stimulate cardiac hypertrophic remodelling but blocking the aldosterone receptor did not prevent myocyte hypertrophy for the investigators.
Still, the heart is small in terms of mass, and the skeletal muscle tissue mass is vastly greater. The net effect of systemic corticosteroid dosing is the mobilisation of amino acids. Wise et al (1973) found that the plasma alanine level increased by about 40% after three days of daily dexamethasone (2mg). Specifically, alanine is the amino acid that increases the most, which pushes fuel into the alanine cycle (otherwise known as the Cahill cycle), where it can act as the substrate for hepatic gluconeogenesis (i.e. the liver can create pyruvate from it). Thus, the net result of corticosteroids is the conversion of structural muscle protein into metabolic fuel.
But why, the reader might exclaim, looking at a mechanism that can't possibly be helpful in any way. Why would your own glucocorticoids want to do this. Well, reader, the stress response calls for desperate measures, and corticosteroids released in response to stress are analogous to a government commandeering the resources of the private economy during wartime. Braun & Marks (2015) explain this much better, and without lame military analogies. The long and short of it is that a systemic response to stress requires metabolic fuel in the form of glucose to be readily available and abundant, as well as free amino acids to act as substrates for the synthesis of acute phase reactants and the replication of immune cells. This sort of repurposing of skeletal muscle protein is probably a safe sacrifice to make when you are fighting off an episode of sepsis, as this will be shortlived and your robust young organism will probably not miss the 2% of the muscle mass that might disappear in this fashion every day.
Unfortunately, from an evolutionary standpoint, these sorts of quick acute stressors are all you were ever expected to handle before you had the opportunity to sow your reproductive oats. No illness more severe, or more prolonged, had yielded much of an evolutionary pressure, as our ancestors would have inevitably died, and so you lack the mechanisms to control this hypercatabolic process - there was simply no reason for them to ever evolve. Fortunately, modern man has the benefit of some highly developed critical care services, and can remain profoundly ill for weeks and weeks, during which time this increasingly dysfunctional and misdirected stress response can devastate their muscle tissue through catabolism.
There is a widespread belief among the medical community that corticosteroid therapy produces an increased risk of peptic ulcers. This belief was originally based on some data from the 1980s and 1990s which, according to Fardet et al (2007), were not entirely sound, at least in terms of drawing such firm conclusions. Looking at the (non-blinded, largely retrospective observational) studies, one fails to be impressed by the methodological rigor, and when later investigators pooled data from only respectable sources, the difference in peptic ulcer risk turned out to be 0.3% vs 0.4%. In the cold light of this modern enlightened era, Narum et al (2014) were ultimately able to identify some groups of increased risk (mainly hospitalised inpatients and the critically ill), in whom the rate of GI bleeding was increased by about 40%. However, the overall risk was very small - in the entire population (33,253 participants from 159 trials), only 2.5% of patients had this complication (2.9% in the steroid group).
The mechanism underlying this increase in risk is not especially clear. In fact it appears that under normal physiological conditions glucocorticoids are actually gastroprotective. It is now believed that corticosteroids in vastly supraphysiological doses probably just make the gastric mucosa more vulnerable to other ulcer-generating stresses, and then prevent wound healing to exacerbate the injury. For example, Takeuchi et al (2007) were able to produce gastic ulceration in rats using prednisolone, but they had to give them 50mg/kg of the drug (a completely insane overdose for a human), and the rats had to have COPD for this to work (they were exposed to twelve weeks of cigarette smoke). Clearly, multiple factors must conspire to produce this steroid complication, and steroids alone are probably not to blame.
Corticosteroids stimulate bone resorption by their direct activity on osteoclasts. Fardet et al (2007) list the molecular mechanisms, which basically consist of turning off the protective regulatory signals (OPG) while at the same time activating osteoclasts via a soluble cytokine pathway (RANKL). The net effect is osteoporosis, to which female patients are more vulnerable. The dose required to achieve bone loss is anything more than 5mg prednisolone, and the density bone loss is maximal over the first 6 months (10%), decreasing to 2-5% per year for the subsequent years.
This is a bizarre idiosyncratic complication of steroid therapy which probably needs to be mentioned as an aside, even though it dose not belong in a discussion of the "physiological effects of corticosteroid therapy". Nobody seems to have a clear explanation of how it happens, with fat hypertrophy, fat emboli or intravascular thrombosis all identified as possible mechanisms. It can occur at all skeletal sites, but seems to prefer the femoral head, and is surprisingly common (Chan & Mok, 2012, report that it is responsible for something like 10% of the total hip replacements in the US. It appears that the cumulative dose of steroids is the most important association, and the timeframe for the development of this complication is measured in months.
Following even the first dose of steroids, the white cell count is usually seen to increase, and this finding is dismissed by clinicians as something completely expected and unremarkable. The cells that appear in the circulation are mainly neutrophils, and they appear within the first 24 hours following a dose, remaining raised for at least two weeks during sustained treatment and then slowly decreasing (Shoenfeld et al, 1981). That could get confusing if you also suspect the patient of having an infection. Fortunately, steroid-induced leukocytosis is usually without a left shift or toxic granulation, making it a bit easier to distinguish from a genuine inflammatory reaction. The mechanism behind this seems to be a combination of impaired tissue sequestration, increased release from the bone marrow, and decreased apoptosis (all laudable steps in a stress response where you expect an infection). There does not seem to be much of a dose-response relationship, with a similar magnitude of leukocytosis seen with 5mg and 80mg of prednisolone.
Being something of a wet blanket for protein synthesis and cell proliferation, it is no surprise that steroids have a negative effect on tissue repair and wound healing. They interfere with it at every stage: the early macrophage infiltration, the angiogenesis and fibroplasia, the fibroblast proliferation, and the deposition and remodelling of scar collagen.
What is the functional effect on wound integrity? Wang et al (2013) cite numerous horrific-sounding animal studies that have quantified this effect by inflicting wounds on steroid-treated animals and then putting quantifiable graded tension on the edges. The decrease in wound edge tensile strength is apparently about 30%. However, it is difficult to generalise this to the human population, as the doses of steroids required have been massive (15-40mg/kg of prednisolone) and there is clearly a lot of inter-species variability (for example, guinea pigs are completely unaffected). Human patients with Cushing syndrome seemed to have cutaneous wound tensile strength reduced by 40% (in one study from the 19050s with only five patients).
How does this poor wound healing affect the ICU population, from the perspective of clinical outcomes? From the literature review by Wang et al, it would appear that in this sort of chronic setting the risk of wound breakdown (eg. anastomotic leak) is about 2-5 times greater than in the general population. For patients only recently commenced on steroids, there does not appear to be much of an effect over the first ten or so days of therapy. Moreover, some animal data suggests that after three days the main fibroproliferative steps have already been taken and the integrity of the wound will be maintained even in the face of steroid therapy. The surgeon who complains about the stress dose steroids being given to their septic patient should be reminded that uncontrolled septic shock with massive noradrenaline doses also has a negative effect on the anastomotic site.
After a prolonged course of steroids, the abrupt cessation of treatment can produce a withdrawal syndrome which is only partially accounted for by the adrenal suppression. Hochberg et al (2003), discussing endocrine withdrawal syndromes, have a great section on glucocorticoids which goes into some of the suspected mechanisms, which is a great read even though the majority of what is said there seems to be largely speculative.
When steroids are abruptly ceased:
The most amazing version of this is the effect of pituitary resection on patients suffering with classical Cushing's disease, where a secretory ACTH-oma is removed, and the chronically maxed-out adrenal cortisol secretion suddenly stops. By post-operative day 4, Papanicolau et al (1996) noted all patients developed some degree of nausea, anorexia, somnolence and fatigue. Not everyone had fevers, but on average their temperature increased by about 0.6º C. With the immunosuppressant effects of cortisol now removed, the immune system awakens, showering systemic cytokines and producing a syndrome that resembles sepsis biochemically (for example, in the aforementioned case series, the IL-6 levels increased five-fold, with slightly lower rises in TNFα and IL-lβ). The
Remembering that one possible application of corticosteroids is a "pulsed" mega-course in doses of 1000mg per day for several days in a row, one can only but wonder: what even is an "overdose"? Historical examples of heroic steroid use are crowned by Woods et al (1973), who gave twenty-five grams of methylprednisolone to a renal transplant patient over the course of three weeks. That was a 50kg female patient who apparently did well, begging the question: how much is too much?
Well. Most "corticosteroid overdose" occurs subacutely, and represents either overzealous use or some kind of dose miscalculation, such as in this case report by Rottenstreich (2015) where a seven month old was accidentally given five times more dexamethasone than was planned, and developed Cushing syndrome. That's probably not what most people would be thinking of when they say "overdose", even though it is an unexpectedly high dose. When administering pulse steroids, some immediate adverse effects are also seen: Min et al, 2012, followed a group of patients and found abdominal pain and rash were the most commonly reported effects of high dose IV methylprednisolone, followed by hot flushes, a feeling of general weakness, constipation, insomnia, and facial swelling. Other authors also report arrhythmias, tachycardia and bradycardia both, as well as AV block, though nobody died and everything was very self-limiting.
Overall, even after discussing all these side effects and adverse reactions, the incredible harmlessness of these substances needs to be pointed out as a startling and remarkable feature. Consider corticosteroids in the context of other endocrine hormones (adrenaline, insulin, thyroid hormone, etc), and behold their enviable safety profile. Think about it: there are very few endogenous substances where, following the administration of an exogenous dose one hundred times the normal level, nothing serious happens.
Williams, Dennis M. "Clinical pharmacology of corticosteroids." Respiratory care 63.6 (2018): 655-670.
Buchman, Alan L. "Side effects of corticosteroid therapy." Journal of clinical gastroenterology 33.4 (2001): 289-294.
Fardet, Laurence, et al. "Corticosteroid-induced adverse events in adults." Drug safety 30.10 (2007): 861-881.
Poetker, David M., and Douglas D. Reh. "A comprehensive review of the adverse effects of systemic corticosteroids." Otolaryngologic Clinics of North America 43.4 (2010): 753-768.
Magomedova, Lilia, and Carolyn L. Cummins. "Glucocorticoids and metabolic control." Metabolic Control (2015): 73-93.
Fauci, Anthony S. "Mechanisms of the immunosuppressive and anti-inflammatory effects of glucorcorticosteroids." Journal of immunopharmacology 1.1 (1978): 1-25.
Baschant, Ulrike, and Jan Tuckermann. "The role of the glucocorticoid receptor in inflammation and immunity." The Journal of steroid biochemistry and molecular biology 120.2-3 (2010): 69-75.
Hawkins, Donald B., Dennis M. Crockett, and Tony K. Shum. "Corticosteroids in airway management." Otolaryngology—Head and Neck Surgery 91.6 (1983): 593-596.
Horvath, G., and A. Wanner. "Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma." European Respiratory Journal 27.1 (2006): 172-187.
Kumar, Sunil D., et al. "Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma." American journal of respiratory and critical care medicine 161.3 (2000): 918-921.
Hirst, Stuart J., and Tak H. Lee. "Airway smooth muscle as a target of glucocorticoid action in the treatment of asthma." American Journal of Respiratory and Critical Care Medicine 158.supplement_2 (1998): S201-S206.
Weil, Max H. "The cardiovascular effects of corticosteroids." Circulation 25.4 (1962): 718-725.
Kurland, George S., and A. Stone Freedberg. "The Potentiating Effect of ACTH and of Cortisone on Pressor Response to Intravenous Infusion of L-Nor-Epinephrine." Proceedings of the Society for Experimental Biology and Medicine 78.1 (1951): 28-31.
Jain, Rajesh, et al. "Cardiovascular effects of corticosteroid pulse therapy: a prospective controlled study on pemphigus patients." International journal of dermatology 44.4 (2005): 285-288.
Ullian, Michael E. "The role of corticosteroids in the regulation of vascular tone." Cardiovascular research 41.1 (1999): 55-64.
Boyer, A., et al. "Glucocorticoid treatment in patients with septic shock: effects on vasopressor use and mortality." International Journal of Clinical Pharmacology & Therapeutics 44.7 (2006).
d'Emmanuele di Villa Bianca, R., et al. "Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP‐sensitive potassium channels activity." British journal of pharmacology 140.1 (2003): 91-96.
Ciriaco, Miriam, et al. "Corticosteroid-related central nervous system side
Boston Collaborative Drug Surveillance Program. "Acute adverse reactions to prednisone in relation to dosage." Clinical Pharmacology & Therapeutics 13.5part1 (1972): 694-698.
effects." Journal of Pharmacology and Pharmacotherapeutics 4.1_suppl (2013): S94-S98.
Wang, Yimei, et al. "Corticosteroid Therapy and Respiratory Muscle Function in Humans1-3." (1991).
Morrison-Nozik, Alexander, et al. "Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program." Proceedings of the National Academy of Sciences 112.49 (2015): E6780-E6789.
Casuso, Rafael A., et al. "Glucocorticoids improve high-intensity exercise performance in humans." European journal of applied physiology 114.2 (2014): 419-424.
Duclos, Martine. "Evidence on ergogenic action of glucocorticoids as a doping agent risk." The Physician and sportsmedicine 38.3 (2010): 121-127.
Gupta, Anu, and Yashdeep Gupta. "Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment." Indian journal of endocrinology and metabolism 17.5 (2013): 913.
Haran, Michal, et al. "Acute steroid myopathy: a highly overlooked entity." QJM: An International Journal of Medicine 111.5 (2018): 307-311.
El Ghorayeb, Nada, Isabelle Bourdeau, and André Lacroix. "Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism." Frontiers in Endocrinology 7 (2016): 72.
GRABER, ALAN L., et al. "Natural history of pituitary-adrenal recovery following long-term suppression with corticosteroids." The Journal of Clinical Endocrinology & Metabolism 25.1 (1965): 11-16.
Helfer, Elizabeth L., and Leslie I. Rose. "Corticosteroids and adrenal suppression." Drugs 38.5 (1989): 838-845.
Briassoulis, George, et al. "The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors." Endocrine Practice 17.6 (2011): 941-948.
Streck, William F., and Dean H. Lockwood. "Pituitary adrenal recovery following short-term suppression with corticosteroids." The American journal of medicine 66.6 (1979): 910-914.
Ackerman, George L., and Charles M. Nolan. "Adrenocortical responsiveness after alternate-day corticosteroid therapy." New England Journal of Medicine 278.8 (1968): 405-409.
Andrews, Robert C., and Brian R. Walker. "Glucocorticoids and insulin resistance: old hormones, new targets." Clinical science 96.5 (1999): 513-523.
Rizza, Robert A., Lawrence J. Mandarino, and John E. Gerich. "Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action." The Journal of Clinical Endocrinology & Metabolism 54.1 (1982): 131-138.
Radhakutty, Anjana, and Morton G. Burt. "Management of endocrine disease: critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia." European journal of endocrinology 179.4 (2018): R207-R218.
Radhakutty, Anjana, and Morton G. Burt. "Management of endocrine disease: critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia." European journal of endocrinology 179.4 (2018): R207-R218.
Divertie, Gavin D., Michael D. Jensen, and John M. Miles. "Stimulation of lipolysis in humans by physiological hypercortisolemia." Diabetes 40.10 (1991): 1228-1232.
Xu, Chong, et al. "Direct effect of glucocorticoids on lipolysis in adipocytes." Molecular endocrinology 23.8 (2009): 1161-1170.
Rebuffe-Scrive, M., et al. "Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism." Physiology & behavior 52.3 (1992): 583-590.
Ren, Rongqin, et al. "Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis." Endocrinology 153.11 (2012): 5346-5360.
Braun, Theodore P., and Daniel L. Marks. "The regulation of muscle mass by endogenous glucocorticoids." Frontiers in physiology 6 (2015): 12.
Wise, Jonathan K., Rosa Hendler, and Philip Felig. "Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man." The Journal of clinical investigation 52.11 (1973): 2774-2782.
Wandrag, Liesl, et al. "Exploration of muscle loss and metabolic state during prolonged critical illness: Implications for intervention?." PloS one 14.11 (2019): e0224565.
Narum, Sigrid, Tone Westergren, and Marianne Klemp. "Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis." BMJ open 4.5 (2014): e004587.
Byun, Sang Kuk, et al. "The role of corticosteroids in stress-induced gastric ulceration in rats." Laboratory Animal Research 23.2 (2007): 127-131.
Filaretova, Ludmila. "Glucocorticoids are gastroprotective under physiologic conditions." Therapeutic Advances in Chronic Disease 2.5 (2011): 333-342.
Takeuchi, Yoshiaki, Maki Takahashi, and Jun-ichi Fuchikami. "Vulnerability of gastric mucosa to prednisolone in rats chronically exposed to cigarette smoke." Journal of pharmacological sciences 106.4 (2008): 585-592.
Chan, K. L., and C. C. Mok. "Glucocorticoid-induced avascular bone necrosis: diagnosis and management." The open orthopaedics journal 6 (2012): 449.
Frenkel, Amit, et al. "Estimations of a degree of steroid induced leukocytosis in patients with acute infections." The American Journal of Emergency Medicine 36.5 (2018): 749-753.
Shoenfeld, Y., et al. "Prednisone-induced leukocytosis: influence of dosage, method and duration of administration on the degree of leukocytosis." The American journal of medicine 71.5 (1981): 773-778.
Wang, Audrey S., Ehrin J. Armstrong, and April W. Armstrong. "Corticosteroids and wound healing: clinical considerations in the perioperative period." The American journal of surgery 206.3 (2013): 410-417.
Hochberg, Ze’ev, Karel Pacak, and George P. Chrousos. "Endocrine withdrawal syndromes." Endocrine reviews 24.4 (2003): 523-538.
Papanicolaou, DIMITRIS A., et al. "Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency?." The Journal of Clinical Endocrinology & Metabolism 81.6 (1996): 2303-2306.
Woods, John E., et al. "High-dosage intravenously administered methylprednisolone in renal transplantation: a preliminary report." Jama 223.8 (1973): 896-899.
Rottenstreich, A. "Dexamethasone overdose." Reactions 1570 (2015): 74-26.
Min, Kyung Hyun, et al. "Characteristics of adverse effects when using high dose short term steroid regimen." Korean Journal of Audiology 16.2 (2012): 65.
Vasheghani-Farahani, Ali, et al. "Incidence of various cardiac arrhythmias and conduction disturbances due to high dose intravenous methylprednisolone in patients with multiple sclerosis." Journal of the Neurological Sciences 309.1-2 (2011): 75-78.